Janux Therapeutics, Inc. JANX 深 滬
已收盤 08-29 16:00:00 美东时间
22.72
-0.330
-1.43%
華盛通- 最 高23.63
- 今 開23.10
- 成交量 45.63万股
- 最 低 22.46
- 昨 收 23.05
- 總市值 13.44亿
- 52周最高 71.71
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 21.9707
- 委 比 -14.46%
- 總股本 5917.52万
- 歷史最高 71.71
- 量 比 0.93
- 振 幅 5.08%
- 歷史最低 5.65
- 每 手 1
- 風險率 12.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Piper Sandler initiates coverage of oncology companies
Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: CG Oncology (NASDAQ:CGON) rated Overweight with a $55 price target: "Investor expectations for cr...
08-19 23:17
Piper Sandler Initiates Coverage On Janux Therapeutics with Overweight Rating, Announces Price Target of $42
Piper Sandler analyst Kelsey Goodwin initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Overweight rating and announces Price Target of $42.
08-19 20:14
Janux Therapeutics Announces The Dosing Of The First Patient In Its TRACTr Collaboration With Merck; First Patient Dosed In The Lead Collaboration Program Triggers A $10M Milestone Payment To Janux
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell
08-06 04:44
Janux Therapeutics Showcases Advancements In TRACTr, TRACIr, And ARM Platforms Ahead Of 2026 Trials At R&D Day Webcast
PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses.TROP2-TRACTr adds first-in-class
07-25 04:28
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
07-16 01:35
Raymond James Initiates Coverage On Janux Therapeutics with Outperform Rating, Announces Price Target of $65
Raymond James analyst Sean McCutcheon initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Outperform rating and announces Price Target of $65.
07-11 21:03
SA Asks: Which oncology companies are attractive M&A targets?
Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology (NASDA...
05-31 03:00
Janux Therapeutics Initiates Phase 1b Expansion Studies In Ongoing ENGAGER-PSMA-01 Trial
Phase 1b expansion study initiated in taxane-naïve mCRPC patientsUpdated data from Phase 1a dose escalation support initiation of Phase 1b dose expansionUpdates on JANX007 and JANX008 expected in the second half of
05-05 20:37
Analysts’ Top Healthcare Picks: Xenon (XENE), Janux Therapeutics Inc (JANX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
03-06 21:00
美股大行评级 | Piper Sandler：上调ACNB Corp评级至"超配"，目标价从37美元升至50美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1103601922058588161.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持Rocket Pharmaceuticals(RCKT)"跑赢大市"评级，目标价从51美元升至52美元</p> <p>• HC Wainwright & Co.：维持Revolution Medici
03-04 08:54
